SAB Biotherapeutics, Inc. Operating Income Loss

Quick Answer

SAB Biotherapeutics, Inc. reported Operating Income Loss of -$48.95 million for the year ending 2025.

  • SAB Biotherapeutics, Inc. showed a decrease of -14.1% in Operating Income Loss from 2024 to 2025.
  • This data is from SAB Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2020 to 2025), SAB Biotherapeutics, Inc.'s Operating Income Loss has declined by 338.1%.
  • Historical annual values: Fiscal year 2025: -$48.95 million | Fiscal year 2024: -$42.91 million | Fiscal year 2023: -$38.08 million | Fiscal year 2022: -$28.92 million | Fiscal year 2021: -$13.39 million | Fiscal year 2020: $20.56 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: